Summit Therapeutics Inc. (NASDAQ:SMMT) Q4 2023 Earnings Call Transcript

Allen Yang: Around HARMONi-3, I don’t think we’ve disclosed this. I’ll turn to Dave, but I’ll just say that you can sort of calculate enrollment based on the KEYNOTE 407. I think that’s the key benchmark. And what’s interesting, Hartaj, is the squamous non-small cell lung cancer population, or that space has become a lot less crowded recently. So I think that will give us a lot of freedom to operate. I don’t know, Dave, if you want to add anything to our disclosures.

Dave Gancarz: Thanks, Allen. So, at this point, what we have disclosed is that the HARMONi studies, we plan to complete enrollment in the second half of 2024, the second half of this year. We haven’t given further guidance with respect to the regulatory process there, except that we have our coprimary endpoints. From a HARMONi-3 perspective, we just began enrollment in the fourth quarter of 2023, and we’ve yet to give the guidance in terms of when that will complete, but we’re currently enrolling and are excited about moving quickly in that setting as well.

Hartaj Singh: Great. Thank you, everyone. Thanks for the updates.

Operator: Don’t have any raised hands right now, So I’d now like to hand back over to Dave Gancarz. Thank you.

Dave Gancarz: I just want to thank everyone for attending our call and your continued interest in Summit. An archived version of this webcast will be available later today on our website, www.smmttx.com. I want to thank everyone again and enjoy the rest of your day. Thank you.

Operator: Thank you so much for attending today’s session. Have a wonderful day.